Rosuvastatin Side Effects: What to Expect and When to Seek Help

Most people who take rosuvastatin tolerate it well. However, like all statins, it can cause side effects in some individuals.

• Headache: usually mild and transient, particularly during the first few weeks
• Muscle pain (myalgia): the most commonly discussed statin side effect. Typically presents as a generalised ache or stiffness, often in the legs or lower back
• Abdominal pain and nausea: usually settle within a few weeks of starting treatment
• Dizziness: reported occasionally, especially in the early stages
• Constipation: may respond to increased fluid and fibre intake

These side effects are generally mild to moderate and often improve as the body adjusts to the medicine.

If they persist beyond 4 to 6 weeks or significantly affect your daily life, speak with your prescriber.

The BNF notes that side effects tend to be dose-related. This means that higher doses (such as 40 mg) are more likely to cause problems than lower doses (5 mg or 10 mg).

Muscle-related side effects are the most significant concern with all statins, including rosuvastatin. It is important to understand the spectrum of severity.

Myalgia (muscle pain without CK elevation):

• Affects approximately 5 to 10% of statin users in observational studies
• Presents as muscle soreness, tenderness or weakness, often symmetrical
• Blood creatine kinase (CK) levels are normal
• Usually manageable and does not require stopping the medicine

Myopathy (muscle pain with CK elevation):

• Less common (estimated at less than 1 in 1,000)
• CK levels are elevated above 10 times the upper limit of normal
• Requires stopping rosuvastatin and specialist review

Rhabdomyolysis (severe muscle breakdown):

• Very rare but potentially life-threatening
• Massive CK elevation with myoglobin release into the blood
• Can cause acute kidney injury
• Requires emergency hospital treatment

Risk factors for muscle problems:

• Higher rosuvastatin doses (particularly 40 mg)
• Age over 70 years
• Renal impairment
• Hypothyroidism
• Concurrent use of interacting medicines (fibrates, ciclosporin)
• Asian ethnicity (particularly those of East Asian descent, who may have higher rosuvastatin plasma levels)

If you experience unexplained muscle pain, tenderness or weakness, particularly if accompanied by dark urine or fever, contact your prescriber promptly.

Rosuvastatin, like other statins, can cause elevations in liver transaminases (ALT and AST). This is usually detected on routine blood tests rather than through symptoms.

What to know about liver monitoring:

• Liver function tests (LFTs) are typically checked before starting rosuvastatin and then at 3 months after initiation or dose increase
• Most elevations are mild (less than 3 times the upper limit of normal) and transient
• Significant elevations (more than 3 times the upper limit of normal) require dose reduction or discontinuation
• Clinically significant liver injury from statins is extremely rare

Symptoms of liver problems (rare):

• Unexplained fatigue
• Loss of appetite
• Dark urine
• Yellowing of the skin or whites of the eyes (jaundice)

If you notice these symptoms, contact your prescriber for urgent blood tests.

The BNF advises that rosuvastatin should be discontinued if serious liver injury with clinical symptoms or hyperbilirubinaemia is suspected.

NICE guidance emphasises that routine periodic liver function testing beyond the initial check is not necessary for most patients on stable statin therapy.

The following side effects are reported less frequently but are worth being aware of:

Uncommon (1 in 100 to 1 in 1,000):

• Rash, itching or urticaria
• Raised blood glucose (this is a class effect of statins and may be relevant for people at risk of type 2 diabetes)
• Increased HbA1c

Rare (1 in 1,000 to 1 in 10,000):

• Pancreatitis
• Peripheral neuropathy (numbness or tingling in hands and feet)
• Memory impairment or cognitive effects (the MHRA has noted reports, though the evidence for a causal link remains uncertain)
• Interstitial lung disease (very rare, reported with several statins)

Very rare:

• Stevens-Johnson syndrome
• Gynaecomastia (breast enlargement in men)
• Tendon disorders

The benefit-risk balance of rosuvastatin remains strongly positive for the vast majority of patients.

Statins reduce cardiovascular events and mortality, and NICE recommends them as a cornerstone of cardiovascular risk management.

If you experience an unusual symptom after starting rosuvastatin, report it to your prescriber and via the Yellow Card Scheme.

Most rosuvastatin side effects can be managed without stopping treatment. Here are practical strategies:

For muscle pain:

• Your prescriber may check your CK level and thyroid function
• Ensuring adequate vitamin D levels may help (deficiency is common and can contribute to myalgia)
• A trial of dose reduction (e.g. from 20 mg to 10 mg) may resolve symptoms while maintaining lipid control
• Switching to an alternative statin (e.g. pravastatin or pitavastatin) is an option if myalgia persists
• In some cases, intermittent dosing (e.g. rosuvastatin every other day) can be effective due to its long half-life

For gastrointestinal symptoms:

• Taking rosuvastatin with food may reduce nausea
• Increasing fluid and dietary fibre can help with constipation
• Symptoms often settle within the first 2 to 4 weeks

For headache and dizziness:

• Usually transient and resolve spontaneously
• If persistent, dose reduction may help

General advice:

• Attend all scheduled blood tests (lipid profile, LFTs, CK if symptomatic)
• Do not stop rosuvastatin without discussing with your prescriber, as the cardiovascular benefits are significant
• Keep a record of any symptoms and their timing to help your prescriber make informed decisions

The NHS rosuvastatin page provides additional practical information.